Invesco Ltd. Argenx Se Transaction History

Invesco Ltd.

$600 Billion
Q3 2025

A detailed history of Invesco Ltd. transactions in Argenx Se stock. As of the latest transaction made, Invesco Ltd. holds 84,919 shares of ARGX stock, worth $77.1 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

84,919

Previous 243,746 65.16%

Holding current value

$77.1 Million

Previous $134 Million 53.38%

% of portfolio

0.01%

Previous 0.02%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	SELL	$538.64 - $768.0 $85.6 Million - $122 Million	-158,827 Reduced 65.16%	84,919 $62.6 Million
Q2 2025 Aug 13, 2025	SELL	$532.27 - $656.65 $74 Million - $91.3 Million	-138,995 Reduced 36.32%	243,746 $134 Million
Q1 2025 May 12, 2025	SELL	$571.0 - $671.75 $12.1 Million - $14.3 Million	-21,275 Reduced 5.27%	382,741 $227 Million
Q4 2024 Feb 13, 2025	SELL	$520.52 - $638.33 $15.4 Million - $18.8 Million	-29,500 Reduced 6.8%	404,016 $248 Million
Q3 2024 Nov 12, 2024	BUY	$434.22 - $551.9 $101 Million - $128 Million	232,044 Added 115.17%	433,516 $235 Million

Q2 2024 Aug 13, 2024	SELL	$356.01 - $451.55 $77.5 Million - $98.3 Million	-217,683 Reduced 51.93%	201,472 $86.6 Million
Q1 2024 May 14, 2024	SELL	$356.95 - $413.29 $6.1 Million - $7.06 Million	-17,078 Reduced 3.91%	419,155 $165 Million
Q4 2023 Feb 12, 2024	BUY	$338.91 - $506.01 $1.85 Million - $2.76 Million	5,446 Added 1.26%	436,233 $166 Million
Q3 2023 Nov 13, 2023	BUY	$369.35 - $548.43 $126 Million - $187 Million	340,482 Added 377.04%	430,787 $212 Million
Q2 2023 Aug 11, 2023	BUY	$360.14 - $422.58 $11.9 Million - $14 Million	33,036 Added 57.69%	90,305 $35.2 Million
Q1 2023 May 12, 2023	SELL	$334.23 - $403.65 $5.2 Million - $6.28 Million	-15,558 Reduced 21.36%	57,269 $21.3 Million
Q4 2022 Feb 13, 2023	BUY	$342.17 - $402.31 $8.5 Million - $10 Million	24,847 Added 51.79%	72,827 $27.6 Million
Q3 2022 Nov 14, 2022	BUY	$343.2 - $395.75 $4.84 Million - $5.58 Million	14,106 Added 41.64%	47,980 $16.9 Million
Q2 2022 Aug 15, 2022	BUY	$269.58 - $378.88 $45,289 - $63,651	168 Added 0.5%	33,874 $12.8 Million
Q1 2022 May 16, 2022	SELL	$254.45 - $351.06 $4.16 Million - $5.74 Million	-16,364 Reduced 32.68%	33,706 $10.6 Million
Q4 2021 Feb 14, 2022	BUY	$272.01 - $353.03 $417,535 - $541,901	1,535 Added 3.16%	50,070 $17.5 Million
Q3 2021 Nov 15, 2021	BUY	$295.0 - $350.58 $200,305 - $238,043	679 Added 1.42%	48,535 $14.7 Million
Q2 2021 Aug 17, 2021	SELL	$257.11 - $319.92 $58.7 Million - $73.1 Million	-228,339 Reduced 82.67%	47,856 $14.4 Million
Q1 2021 May 17, 2021	BUY	$268.3 - $380.31 $8.55 Million - $12.1 Million	31,854 Added 13.04%	276,195 $76.1 Million
Q4 2020 Feb 16, 2021	SELL	$248.13 - $308.36 $14.8 Million - $18.4 Million	-59,756 Reduced 19.65%	244,341 $71.9 Million
Q3 2020 Nov 16, 2020	SELL	$215.51 - $272.51 $13 Million - $16.4 Million	-60,165 Reduced 16.52%	304,097 $79.8 Million
Q2 2020 Aug 14, 2020	BUY	$127.44 - $232.72 $46.4 Million - $84.8 Million	364,262 New	364,262 $82 Million
Q4 2019 Feb 14, 2020	SELL	$106.59 - $164.21 $343,326 - $528,920	-3,221 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$113.31 - $150.51 $1.16 Million - $1.54 Million	-10,220 Reduced 76.04%	3,221 $367,000
Q2 2019 Aug 14, 2019	SELL	$115.0 - $141.58 $2.53 Million - $3.11 Million	-21,960 Reduced 62.03%	13,441 $1.9 Million
Q1 2019 May 15, 2019	SELL	$98.85 - $134.59 $1.49 Million - $2.03 Million	-15,070 Reduced 29.86%	35,401 $4.42 Million
Q4 2018 Feb 14, 2019	BUY	$63.81 - $109.82 $3.22 Million - $5.54 Million	50,471 New	50,471 $4.85 Million

Others Institutions Holding ARGX

# of Institutions

526

Shares Held

26M

Call Options Held

590K

Put Options Held

320K

View Full List

About ARGENX SE

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $50.2B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

More about ARGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account